Sickle Cell Disease Treatment Market to Exhibit a CAGR of 18.5% and Reach USD 7.71 Billion by 2027; FDA Approval for Emmaus’s Endari to Aid Development, states Fortune Business Insights™
Key Prominent Players Covered in the Sickle Cell Disease Treatment Market Research Report Are Novartis AG (Basel, Switzerland), Global Blood Therapeutics Inc. (California, U.S.), Emmaus Medical Inc. (California, U.S.), Addmedica (Paris, France), Medunik USA Inc. (Pennsylvania, U.S.), Bristol-Myers Squibb Company (New York City, U.S.) and other key market players.
January 20, 2021 08:56 ET
| Source:
Fortune Business Insights
Fortune Business Insights
Pune, India, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The
global sickle cell disease treatment market size is expected to reach USD 7.71 billion in 2027, exhibiting a CAGR of 18.5% during the forecast period. The unmet needs of patients and lack of novel therapies has resulted in research grants from governments, which, in turn, will promote the growth of the market, states Fortune Business Insights, in a report, titled “Sickle Cell Disease Treatment Market Size, Share & Covid-19 Impact Analysis, By Treatment Modality (Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy (Hydroxyurea and Branded Drugs (Endari, Adakveo, Oxbryta, Zynteglo, CTX001, Mitapivat, and FT-4202))), By End User (Hospitals, Specialty Clinics, and Others), and Regional Forecast, 2020-2027.” The market size stood at USD 1.35 billion in 2019.